Episodes

How precision medicine is moving oncologists away from population-based treatments to more patient-appropriate care. Dr. Lee Newcomer, board-certified oncologist and former SVP of oncology and genetics at UnitedHealthcare, answers pressing questions about the current costs of cancer care, how diagnostics are currently reimbursed and who should control the development of those diagnostics. His answers gave us a lot to think about.

How precision medicine is moving oncologists away from population-based treatments to more patient-appropriate care. Dr. Lee Newcomer, board-certified oncologist and former SVP of oncology and genetics at UnitedHealthcare, answers pressing questions about the current costs of cancer care, how diagnostics are currently reimbursed and who should control the development of those diagnostics. His answers gave us a lot to think about.

Precision Medicine Podcast guest Dr. Sandeep “Bobby” Reddy talks about how he became an early adopter of precision medicine and the opportunities that exist to present its economic benefits. Listen to the full episode here.

Precision Medicine Podcast guest Dr. Sandeep “Bobby” Reddy talks about how he became an early adopter of precision medicine and the opportunities that exist to present its economic benefits. Listen to the full episode here.

Precision Medicine Podcast guest Dr. Sandeep “Bobby” Reddy talks about how he became an early adopter of precision medicine and the opportunities that exist to present its economic benefits. Listen to the full episode here.

In epsiode 6, Dr. Peter Beitsch, Chief Physician of the Dallas Surgical Group and an executive with the TME Breast Cancer Network, joined us to discuss his study published by the Clinical Journal of Oncology titled, Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? During the episode, he spoke in-depth about the results of that study and the implications for the future of precision medicine in cancer care. This episode is Part Two of that discussi...

In epsiode 6, Dr. Peter Beitsch, Chief Physician of the Dallas Surgical Group and an executive with the TME Breast Cancer Network, joined us to discuss his study published by the Clinical Journal of Oncology titled, Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? During the episode, he spoke in-depth about the results of that study and the implications for the future of precision medicine in cancer care. This episode is Part Two of that discussi...

In epsiode 6, Dr. Peter Beitsch, Chief Physician of the Dallas Surgical Group and an executive with the TME Breast Cancer Network, joined us to discuss his study published by the Clinical Journal of Oncology titled, Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? During the episode, he spoke in-depth about the results of that study and the implications for the future of precision medicine in cancer care. This episode is Part Two of that discussi...

Clynt Taylor, CEO of Intervention Insights, shares his insight in working with large cancer centers to identify and address barriers to precision medicine in cancer care.

Clynt Taylor, CEO of Intervention Insights, shares his insight in working with large cancer centers to identify and address barriers to precision medicine in cancer care.

Clynt Taylor, CEO of Intervention Insights, shares his insight in working with large cancer centers to identify and address barriers to precision medicine in cancer care.

In this episode, we welcome guest, Chris Wells, VP of Public Affairs for the Personalized Medicine Coalition, a collaboration of innovators, scientists, patients, providers, and payers who work to further the understanding and adoption of personalized medicine across the healthcare system.

In this episode, we welcome guest, Chris Wells, VP of Public Affairs for the Personalized Medicine Coalition, a collaboration of innovators, scientists, patients, providers, and payers who work to further the understanding and adoption of personalized medicine across the healthcare system.

In this episode, we welcome guest, Chris Wells, VP of Public Affairs for the Personalized Medicine Coalition, a collaboration of innovators, scientists, patients, providers, and payers who work to further the understanding and adoption of personalized medicine across the healthcare system.

Luba Greenwood, J.D., Strategic Business Development at Google Life Sciences, discusses innovative digital health tools in precision medicine and the greater healthcare space.

Luba Greenwood, J.D., Strategic Business Development at Google Life Sciences, discusses innovative digital health tools in precision medicine and the greater healthcare space.

Luba Greenwood, J.D., Strategic Business Development at Google Life Sciences, discusses innovative digital health tools in precision medicine and the greater healthcare space.

In this episode of the Precision Medicine Podcast, Brad Power, a courageous journalistic voice and lymphoma survivor, shares why he's fighting for greater access to precision medicine in clinical practice. Brad has worked as a re-engineering consultant and has authored over 75 articles for the Harvard Business Review.

In this episode of the Precision Medicine Podcast, Brad Power, a courageous journalistic voice and lymphoma survivor, shares why he's fighting for greater access to precision medicine in clinical practice. Brad has worked as a re-engineering consultant and has authored over 75 articles for the Harvard Business Review.

In this episode of the Precision Medicine Podcast, Brad Power, a courageous journalistic voice and lymphoma survivor, shares why he's fighting for greater access to precision medicine in clinical practice. Brad has worked as a re-engineering consultant and has authored over 75 articles for the Harvard Business Review.

In this episode, Jeanette McCarthy, co-founder of Precision Medicine Advisors and genome educator, joins us to discuss the importance of educating everyone involved in precision medicine—including healthcare providers, payers, and even patients—about its day-to-day applications.

In this episode, Jeanette McCarthy, co-founder of Precision Medicine Advisors and genome educator, joins us to discuss the importance of educating everyone involved in precision medicine—including healthcare providers, payers, and even patients—about its day-to-day applications.

In this episode, Jeanette McCarthy, co-founder of Precision Medicine Advisors and genome educator, joins us to discuss the importance of educating everyone involved in precision medicine—including healthcare providers, payers, and even patients—about its day-to-day applications.

NCCN testing guidelines have long been a key tool that payers use to decide which cancer patients will be covered for genetic testing. With the rapid growth of precision medicine, it has become more important than ever to ensure every patient that should be tested is tested, raising new questions about how effectively and consistently current guidelines are applied. Dr. Peter Beitsch addresses some of those questions in a recent study published by the Journal of Clinical Oncology and many are sa...